Can Lyme Disease Cause Brain Lesions on an MRI? What Scans Really Show

Yes, Lyme disease can cause visible abnormalities on an MRI, but true "brain lesions" in the destructive sense are rare. Most Lyme-related MRI findings are nonspecific white matter spots, mild meningeal enhancement, or cranial nerve inflammation rather than fixed lesions. Roughly 10 to 15 percent of patients with neurologic Lyme have abnormal brain MRI results, and the majority of those abnormalities resolve after antibiotic treatment. The finding that matters most is whether a lesion looks like Lyme at all, because multiple sclerosis, stroke, and small vessel disease produce far more convincing lesions.

The Mechanism: How Borrelia Reaches the Brain

Lyme neuroborreliosis begins when Borrelia burgdorferi, the spirochete transmitted by Ixodes ticks, disseminates from the skin into the bloodstream. The bacterium does not produce toxins that dissolve brain tissue. Instead it triggers inflammation in the meninges, the thin membranes surrounding the brain and spinal cord.

That inflammation is the source of nearly every MRI finding attributed to Lyme. Early neurologic Lyme typically causes a lymphocytic meningitis, meaning white blood cells crowd into the cerebrospinal fluid. On a contrast-enhanced MRI, this can appear as subtle enhancement along the meninges or along cranial nerves, most often the facial nerve in Bell's palsy.

The spirochete can also inflame blood vessels, a condition called Lyme vasculitis. When small cerebral arteries narrow, the brain tissue they supply can become ischemic. This is the one pathway by which Lyme genuinely produces infarct-like lesions, and it is uncommon. In plain terms: Lyme irritates the brain's lining and blood vessels far more often than it damages brain tissue directly.

A critical distinction separates inflammation from destruction. Meningeal enhancement and white matter spots are signs of active inflammation and are usually reversible. A demyelinating plaque from multiple sclerosis, or a cavity from an old stroke, is structural damage that persists.

How Often MRI Findings Appear: The Numbers

European and American cohorts give the clearest picture of frequency. In studies of confirmed Lyme neuroborreliosis, roughly 10 to 15 percent of patients show abnormal brain MRI results, and most of those abnormalities are mild.

The table below compares typical MRI findings across conditions that produce similar-looking spots, which is where most diagnostic confusion occurs.

The migraine row matters because it corrects a common assumption. A person with headaches and a few white matter spots may have migraine, not Lyme, even if a tick bite occurred years earlier.

The key quantitative point: nonspecific white matter lesions appear in 30 to 40 percent of migraine sufferers and rise sharply with age, so a handful of spots on an MRI is statistically unremarkable in the general population. Attributing them to Lyme requires evidence beyond the scan.

A Timeline of MRI Changes in Lyme Neuroborreliosis

MRI findings follow a predictable arc, though individual timing varies widely. The table below outlines the typical course from tick bite through resolution.

The timeline carries a professional caveat. Neurologic Lyme can present without a remembered rash, and up to 30 percent of infected people never notice erythema migrans. A normal MRI does not exclude neuroborreliosis, because cerebrospinal fluid analysis, not imaging, confirms the diagnosis.

White Matter Spots: Why They Are Usually Not "Lesions"

The term lesion implies damage, but most Lyme-related white matter spots are better described as nonspecific. They are small, scattered, and typically located in the subcortical white matter rather than clustered around the ventricles the way multiple sclerosis plaques are.

Radiologists use specific features to tell them apart. Multiple sclerosis plaques tend to be ovoid, oriented perpendicular to the ventricles, and located in the periventricular and juxtacortical regions. Lyme spots are fewer, less stereotyped, and less likely to involve the spinal cord or optic nerve.

This distinction changes management. Per the 2020 American Academy of Neurology guidance on neurologic Lyme disease, diagnosis rests on clinical findings plus serologic testing, with cerebrospinal fluid confirmation when the central nervous system is involved. Imaging supports but never establishes the diagnosis.

A non-obvious detail worth flagging: contrast enhancement from Lyme meningitis can persist for weeks after symptoms improve and antibiotics begin. A still-enhancing MRI during treatment does not necessarily mean treatment failed. Clinicians weigh symptoms and cerebrospinal fluid trends, not the scan alone.

Distinguishing Lyme From Multiple Sclerosis and Stroke

The single most important decision after an abnormal MRI is whether the pattern fits Lyme or another disease. This is where misdiagnosis causes the most harm in both directions.

Missing multiple sclerosis because a clinician attributes plaques to Lyme delays disease-modifying therapy. Conversely, attributing stable multiple sclerosis plaques to Lyme exposes patients to repeated antibiotic courses with no benefit and real risk, including Clostridioides difficile infection and catheter complications.

Lyme vasculitis is the exception that can mimic stroke. When Borrelia inflames cerebral arteries, the resulting infarct is a genuine lesion. This presentation is rare, and it requires both serologic confirmation and vascular imaging to support the diagnosis.

Red flags that point away from Lyme and toward another diagnosis:

• Lesions that enlarge or multiply over months despite adequate antibiotics
• Spinal cord involvement, optic neuritis, or lesions in the periventricular pattern typical of multiple sclerosis
• Symptoms that progress steadily without the fluctuating or relapsing pattern typical of treated Lyme
• New focal weakness, speech difficulty, or vision loss suggesting acute stroke
• Imaging changes accompanied by fever and a stiff neck that worsen rather than improve on treatment
• A positive Lyme antibody test with no compatible clinical syndrome, since antibody tests can stay positive for years after past infection

Any of these warrants urgent neurology review and repeat imaging rather than another antibiotic course.

What the MRI Does Not Prove

A central misconception drives much of the online confusion: that a brain lesion on MRI confirms chronic Lyme disease. The evidence does not support that leap.

Serologic testing distinguishes exposure from active infection imperfectly. Immunoglobulin G antibodies can persist for years after successful treatment, so a positive result plus a white matter spot does not establish causation. The 2006 Infectious Diseases Society of America guidelines, reaffirmed in later updates, recommend against prolonged antibiotic therapy for persistent symptoms without objective evidence of active infection, citing randomized trials showing no durable benefit.

Another corrected misconception concerns "Lyme brain lesions" as a distinct entity. No validated imaging signature exists. The published literature describes nonspecific findings, not a recognizable lesion pattern.

In plain terms: an MRI can show that something is inflamed or scarred, but it cannot tell you that Lyme caused it. That determination comes from the clinical picture, antibody testing, and sometimes cerebrospinal fluid analysis together.

What to Actually Do

Concrete steps help patients and clinicians avoid the two failure modes: missing neurologic Lyme and over-treating on the basis of a scan.

• Get a two-tier antibody test if there is a compatible history, such as a rash, tick exposure, or facial palsy, before attributing any MRI finding to Lyme.
• Ask for cerebrospinal fluid analysis when neurologic symptoms and a positive antibody test coexist, since this is the standard for confirming neuroborreliosis.
• Request a radiology read that specifically describes lesion location and pattern, because periventricular ovoid plaques point toward multiple sclerosis, not Lyme.
• Follow up with repeat imaging at 6 to 12 months for unexplained white matter spots, to see whether they evolve.
• Complete the standard 14 to 28 day antibiotic course for confirmed early neurologic Lyme rather than extended therapy.
• Seek neurology referral promptly for any red-flag symptom rather than repeating antibiotics.

In plain terms: test for the infection, image the brain, and let both results, read together by a clinician, guide the decision.

Limitations and the Honest Bottom Line

The evidence base has real gaps. Most Lyme MRI studies are small, drawn from European cohorts where Borrelia garinii and afzelii predominate rather than the North American B. burgdorferi. Findings may not transfer perfectly across strains and regions.

Imaging technology also matters. Many older studies used lower-resolution scanners that missed subtle enhancement visible on modern 3-tesla MRI, so historical frequency estimates of 10 to 15 percent may undercount what current scans detect. Conversely, higher sensitivity also detects more harmless age-related spots, which can inflate apparent Lyme associations.

The honest bottom line reconciles the numbers: brain MRI abnormalities occur in roughly 10 to 15 percent of neurologic Lyme cases, most are nonspecific and reversible, and genuine destructive lesions from Lyme are rare. The scan is a supporting tool, not a verdict. Diagnosis and treatment decisions rest on clinical findings, validated antibody testing, and cerebrospinal fluid analysis, with imaging helping to rule out the conditions that produce far more convincing lesions.